Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. - Wikidata - wikimedia - TriplyDB

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

http://www.wikidata.org/entity/Q51581299

about

Crizotinib: A comprehensive review The biology and treatment of EML4-ALK non-small cell lung cancer Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs ALK inhibitors in non-small cell lung cancer: the latest evidence and developments The distinctive nature of adenocarcinoma of the lung Medical management of lung cancer: Experience in China Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular ALK and ROS1 as a joint target for the treatment of lung cancer: a review Review of the current targeted therapies for non-small-cell lung cancer Molecular pathology of non-small cell lung cancer: a practical guide.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.Ceritinib in ALK-rearranged non-small-cell lung cancer.International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma Lung cancer in never smokers Non-small cell lung cancer in never smokers: a clinical entity to be identified A novel classification of lung cancer into molecular subtypes Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.Molecular pathways and therapeutic targets in lung cancer Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status.Crizotinib: a breakthrough for targeted therapies in lung cancer Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.Mind-mapping for lung cancer: towards a personalized therapeutics approach A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients.Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer.Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis The potential for crizotinib in non-small cell lung cancer: a perspective review Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

P2860

Q24624083-AADC9994-BD6E-4937-A133-FA03C8B761E8 Q24632625-6900200D-DF70-4B04-9E59-42ED0A32F00A Q26741318-9EC2AA62-AFA6-4C9A-8C17-A129C6725E16 Q26769659-215C7295-7C77-4796-8C7C-5619CE358B81 Q26769879-3C54EFB1-080E-401B-8878-0FC4F0AE92C5 Q26781159-A7D3E209-2F9B-4B4C-85E4-59DF91127BB5 Q26798257-5F73F6A2-F7F2-4B8B-8F40-0B01C7E19638 Q26828860-634AC5F7-9406-478A-8D78-78385B081536 Q26851392-5D5F0BDF-8F36-492A-80EC-650BE7E222B7 Q27015079-A6895B2B-1F84-4A86-B8C2-DD7F45F000E6 Q27690919-81DE83BC-F1A4-4721-AE17-724694DF10E5 Q27851671-5779E9D9-7FE1-4775-B076-4AC2AEF4C314 Q27852699-8F965E02-C0F3-409D-BD2A-9900704E94AC Q27852989-36CE81D8-8D37-45B4-A910-FC8E644D2010 Q28303718-9748C4DB-BBC3-4F45-B83C-F77755AE3138 Q28386853-70569DED-9AF6-4F92-AA7C-975FBFB4CB0E Q28393152-E6146001-395F-421B-85FC-579D64C50E21 Q28731874-D7B90DEE-F801-4C87-9F67-FCCE79F78D3C Q31167585-327EEF5B-2AE3-4E4A-BCDD-2988098E20E8 Q33617464-F07BB494-49F7-4E0B-AFD4-2EAE3488EAD7 Q33688872-F80268A3-B013-47F5-9D5E-E75C59B4BA2F Q33733522-7DA81289-CA88-4FC6-9563-A788C5E191F4 Q33885657-891A3513-2B7E-4307-8C3F-524695D8B67A Q34159011-639DA57F-71A9-47BD-B3C8-0F21F31FF285 Q34328665-5318330E-173C-4C86-A685-45C334FCAAEA Q34434003-6834252F-AEEF-4DB6-B8BB-4C416249436E Q34544971-3E1D0033-5F10-4BDC-B764-BBD3AA322375 Q34558207-5D1B5B2F-04F2-44E5-BFFD-A19188138BF5 Q34558586-5A7A9341-F563-4F0B-8B90-E47614DD307B Q34593929-9D856955-E7A1-46C6-A7C8-11648C55D22F Q34620545-8E12E744-098F-43E4-9358-773067B668C9 Q34796086-8B69126F-C49E-489A-ACC1-F1D06A0255B4 Q34924658-3D8BD8B5-8D8B-4C43-94A7-0132FD640256 Q34947842-4A2AB44B-F498-478E-B55B-D3688861DE00 Q35087767-C0B4FC51-DF68-496B-B496-5F051115A677 Q35111284-49DA793C-8A86-4242-98F0-20EFC0351FE9 Q35113209-698437B0-DDB1-4306-9F20-625E24872F6C Q35534514-B97026BA-6F06-4433-9EF0-CA77BE5336CC Q35741716-9B7156AB-091F-48B0-9B52-CA02464C03C9 Q35791225-7E353CB8-5CEF-4832-9A1E-DB94E59F2072

P2860

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

http://www.wikidata.org/entity/Q51581299

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

@en

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

@nl

type

label

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

@en

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

@nl

prefLabel

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

@en

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

@nl

P1433

Q51581299-FE989BDE-483D-4969-BFD9-074B039CF95B

P1476

Q51581299-4FC9923F-6EFE-49CA-8B37-B6ED537AF1AA

P2093

Q51581299-01CC5502-5FAB-4A07-83B9-3C0F5B5934FE

Q51581299-1977FFD4-3516-46F2-B1DA-AA41B3CC6EDB

Q51581299-42108140-8A73-4CEF-9D77-5E9A5DAC194C

Q51581299-4AD6DAEB-183D-4D1A-92AD-CEAD659F7951

Q51581299-58162409-3CAD-4B76-AE7E-B1539F7D3926

Q51581299-7304E553-1B07-4753-A5F6-BEA10D5B6805

Q51581299-74DFA1C4-6D0A-4EA9-B092-C184C30B33CF

Q51581299-9779DF51-7123-4757-8AF6-A350D2287D01

Q51581299-9ADB8D79-E145-40FD-9D91-306553C7AFEF

Q51581299-9F654B9B-E66F-466E-8C4B-CEDD4E5704CD

P2860

Q51581299-2E9355AE-079A-4284-AFD1-DCBF33802A0D

Q51581299-DC86A93F-3F68-4A01-AFD4-E36FCDDDF707

P2888

Q51581299-A959ED95-462D-4B6D-8974-815CAD681703

P304

Q51581299-ACA1D87B-4704-469C-8DB7-6F0B8F89A753

P31

Q51581299-94F415F7-3273-474B-8BD3-45FC4B834F4B

P356

Q51581299-ED5BCF89-6DB2-4549-87BD-56CC6916832F

P433

Q51581299-18C665FA-169C-4060-BB5C-6352D68B30B3

P478

Q51581299-E505762E-C7CF-43E6-B7E2-5EBA550CF9B8

P577

Q51581299-1C36BC2D-645C-44D3-97D7-93EDCAF23C39

P5875

Q51581299-C50C8B4D-A05D-4676-A4CB-3C2096EC36E1

P6179

Q51581299-9CCFBBDC-5E62-4090-8F9E-79DFFDFE5C37

P698

Q51581299-0AC10CB9-C3E8-4678-A333-F36E62F0BC6F

P356

S10434-009-0808-7

P1433

Annals of Surgical Oncology

P1476

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

@en

P2093

Akihiko Yoshizawa

http://www.w3.org/2001/XMLSchema#string

Ei Nakayama

http://www.w3.org/2001/XMLSchema#string

Hiroshi Date

http://www.w3.org/2001/XMLSchema#string

Kenichi Okubo

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Sato

http://www.w3.org/2001/XMLSchema#string

Makoto Sonobe

http://www.w3.org/2001/XMLSchema#string

Masashi Kobayashi

http://www.w3.org/2001/XMLSchema#string

Nobuya Mino

http://www.w3.org/2001/XMLSchema#string

Ryo Miyahara

http://www.w3.org/2001/XMLSchema#string

Shotaro Iwakiri

http://www.w3.org/2001/XMLSchema#string

P2860

EML4-ALK fusion lung cancer: a rare acquired event.

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

P2888

s10434-009-0808-7

P304

889-897

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-009-0808-7

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41564121

http://www.w3.org/2001/XMLSchema#string

P6179

1001051684

http://www.w3.org/2001/XMLSchema#string

P698

20183914

http://www.w3.org/2001/XMLSchema#string